Physician profile
Marlo P Smith
NPI 1326259243
$560.62
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $143 · 2023: $58.86 · 2024: $96.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $136.46 | 2022-2024 | Contrave |
| Innocoll Pharmaceuticals Limited | $111.31 | 2021 | |
| Novo Nordisk INC | $44.37 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Myriad Genetic Laboratories, INC. | $39.67 | 2021 | |
| Heron Therapeutics, INC. | $35.12 | 2021-2022 | |
| Integra Lifesciences Corporation | $35.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.48 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.32 | 2021 | |
| Acacia Pharma INC | $20.65 | 2021 | |
| Baxter Healthcare | $15.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2022 | |
| Endo Pharmaceuticals INC. | $14.06 | 2021 | |
| Reprise Biomedical, INC. | $13.23 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.93 | 2021 | |
| Tactile Systems Technology INC | $12.13 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlo Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.